Efficacy and safety of oral roflumilast for moderate-to-severe psoriasis—a randomized controlled trial (PSORRO)

BACKGROUND: Roflumilast is a targeted inhibitor of phosphodiesterase (PDE)-4 and has been approved for treatment of severe chronic obstructive pulmonary disease for more than a decade. Generic versions are available in the United States. PDE-4 is involved in the psoriasis pathogenesis, but the effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Gyldenløve, Mette, Meteran, Howraman, Sørensen, Jennifer A., Fage, Simon, Yao, Yiqiu, Lindhardsen, Jesper, Nissen, Christoffer V., Todberg, Tanja, Thomsen, Simon F., Skov, Lone, Zachariae, Claus, Iversen, Lars, Nielsen, Mia-Louise, Egeberg, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350848/
https://www.ncbi.nlm.nih.gov/pubmed/37465323
http://dx.doi.org/10.1016/j.lanepe.2023.100639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10350848/
https://www.ncbi.nlm.nih.gov/pubmed/37465323
http://dx.doi.org/10.1016/j.lanepe.2023.100639

Ejemplares similares